{
    "2021-02-19": [
        [
            {
                "time": "2019",
                "original_text": "昭衍新药港股上市首日破发 2019年国内非临床DSA市占率第一 连续下跌",
                "features": {
                    "keywords": [
                        "昭衍新药",
                        "港股",
                        "上市",
                        "破发",
                        "非临床DSA",
                        "市占率",
                        "连续下跌"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "广生堂(300436.SZ)确定泰格医药为乙肝创新药“GST-HG141”Ib期临床试验CRO",
                "features": {
                    "keywords": [
                        "广生堂",
                        "泰格医药",
                        "乙肝",
                        "创新药",
                        "GST-HG141",
                        "Ib期临床试验",
                        "CRO"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "广生堂(300436.SZ)：GST-HG141已完成Ia期临床试验暨确定泰格医药为Ib期临床试验CRO",
                "features": {
                    "keywords": [
                        "广生堂",
                        "GST-HG141",
                        "Ia期临床试验",
                        "泰格医药",
                        "Ib期临床试验",
                        "CRO"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "大摩增持泰格医药(03347)约29.69万股，每股作价180.69港元",
                "features": {
                    "keywords": [
                        "大摩",
                        "增持",
                        "泰格医药",
                        "29.69万股",
                        "180.69港元"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【权益变动】泰格医药(03347-HK)获摩根士丹利增持约29.69万股",
                "features": {
                    "keywords": [
                        "权益变动",
                        "泰格医药",
                        "摩根士丹利",
                        "增持",
                        "29.69万股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "0219",
                "original_text": "晨报0219 | 医药春季策略、新式茶饮行业专题、盘江股份（600395）",
                "features": {
                    "keywords": [
                        "医药春季策略",
                        "新式茶饮",
                        "盘江股份"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "消费"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}